NYSE:MRKMerck & Co., Inc. Stock Price, Forecast & News

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MRK stock has increased by 2.2% and is now trading at $81.02.
View which stocks have been most impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Merck & Co., Inc..

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRK) issued its earnings results on Friday, July, 31st. The company reported $1.37 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.14 by $0.23. The business earned $10.87 billion during the quarter, compared to analyst estimates of $10.52 billion. Merck & Co., Inc. had a net margin of 22.20% and a return on equity of 52.94%. The firm's quarterly revenue was down 7.6% on a year-over-year basis. During the same quarter last year, the firm posted $1.30 earnings per share.
View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. announced a quarterly dividend on Wednesday, July 29th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.61 per share on Wednesday, October 7th. This represents a $2.44 annualized dividend and a yield of 3.01%. The ex-dividend date is Monday, September 14th.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. announced that its board has approved a share repurchase program on Thursday, October 25th 2018, which permits the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 5.1% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's leadership believes its shares are undervalued.

Merck & Co., Inc. issued an update on its FY20 earnings guidance on Friday, July, 31st. The company provided EPS guidance of $5.63-5.78 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.31. The company issued revenue guidance of $47.2-48.7 billion, compared to the consensus revenue estimate of $47.33 billion.

14 analysts have issued 1 year target prices for Merck & Co., Inc.'s shares. Their forecasts range from $89.00 to $105.00. On average, they expect Merck & Co., Inc.'s share price to reach $94.93 in the next twelve months. This suggests a possible upside of 17.2% from the stock's current price.
View analysts' price targets for Merck & Co., Inc..

Media headlines about MRK stock have trended very positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Merck & Co., Inc. earned a news impact score of 4.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Merck & Co., Inc..

Merck & Co., Inc. saw a decrease in short interest in June. As of June 30th, there was short interest totaling 14,560,000 shares, a decrease of 7.9% from the June 15th total of 15,810,000 shares. Based on an average daily trading volume, of 11,610,000 shares, the short-interest ratio is currently 1.3 days. Approximately 0.6% of the company's stock are short sold.
View Merck & Co., Inc.'s Current Options Chain.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Walt Disney (DIS), Cisco Systems (CSCO), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), AbbVie (ABBV) and Exxon Mobil (XOM).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by many different institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.50%), Swiss National Bank (0.43%), Fisher Asset Management LLC (0.36%), PNC Financial Services Group Inc. (0.36%), LSV Asset Management (0.34%) and Principal Financial Group Inc. (0.29%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Thornburg Investment Management Inc., Victory Capital Management Inc., Menora Mivtachim Holdings LTD., Railway Pension Investments Ltd, Robeco Institutional Asset Management B.V., DAVENPORT & Co LLC, Jennison Associates LLC, and Prudential PLC. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Julie L Gerberding, Richard R Deluca, and Wendell P Weeks.
View insider buying and selling activity for Merck & Co., Inc..

MRK stock was bought by a variety of institutional investors in the last quarter, including Sarasin & Partners LLP, Sumitomo Mitsui Trust Holdings Inc., Alecta Pensionsforsakring Omsesidigt, Candriam Luxembourg S.C.A., LSV Asset Management, Strs Ohio, Principal Financial Group Inc., and First Trust Advisors LP.
View insider buying and selling activity for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $81.02.

Merck & Co., Inc. has a market capitalization of $204.92 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

The official website for Merck & Co., Inc. is www.merck.com.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]